|
Unless otherwise indicated, this information has been self-reported and has not been
verified by the Board of Medicine.
Academic Appointments
Last Updated 2/21/2024
Uniformed Services University Of The Health Sciences F. Edward Hébert School Of Medicine - Bethesda MD
Rank: Visiting Research Scientist
Years: 1997-1998
Uniformed Services University Of The Health Sciences F. Edward Hébert School Of Medicine - Bethesda MD
Rank: Research Associate Professor
Years: 1998-2000
Academic Appointments - Non-US
Last Updated 2/21/2024
None Reported
Publications
(up to ten in the last five years)
Last Updated 2/21/2024
Diabetes Obes Metab
Volume: 18
Date: 05 2016
doi: 10.1111/dom.12690
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY EXECUTIVE SUMMARY Complete Guidelines
Endocr Pract
Volume: 22
Date: 07 2016
doi: 10.4158/EP161356.ESGL
Impact on psychosocial outcomes of a nationally available weight management program tailored for individuals with type 2 diabetes: Results of a randomized controlled trial.
J Diabetes Complications
Volume: 31
Date: 05 2017
doi: 10.1016/j.jdiacomp.2017.01.022
Biopsychosocial Modifiers of Obesity
Bariatric Endocrinology: Evaluation and Management of Adiposopathy, Adiposity, and Related Disease
Date: 01 2019
ISBN 978-3-319-95655-8
Changes in Weight Control Behaviors and Hedonic Hunger in a Commercial Weight Management Program Adapted for Individuals with Type 2 Diabetes
International Journal of Obesity
Date: 01 2020
doi.org/10.1038/s41366-020-0530-x
Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial
Obesity
Volume: 28
Date: 01 2020
doi: 10.1002/oby.22726
Weight History in Clinical Practice: The State of the Science and Future Directions
Obesity
Volume: 28
Date: 01 2020
doi: 10.1002/oby.22642
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D; STEP 4 Investigators. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Lo
JAMA
Volume: 325
Date: 04 2021
Efficacy and safety of once-weekly cagrilintide for weight management: a randomised, placebo and active-controlled, dose-finding, phase 2 trial Lancet
Lancet
Date: 11 2021
Rubino DM, Greenway F, Khalid U, O’Neil P, Rosenstock J, Sørrig R, Wadden TA, Witzert A, Garvey WT. Once-weekly semaglutide 2.4 mg vs once-daily liraglutide 3.0 mg in adults with overweight or obesity (STEP 8): a randomised, open label, phase 3 trial
JAMA
Volume: 327
Date: 01 2022
|
